Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review

INTRODUCTION: In the context of the opioid crisis in North America, the benefits of evidence-based opioid agonist treatments such as buprenorphine/naloxone have not been optimised due to low uptake. Numerous factors contribute to the underuse of buprenorphine, and theory-informed approaches to ident...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open
Egile Nagusiak: Leece, Pamela, Khorasheh, Triti, Corace, Kimberly, Strike, Carol, Bayoumi, Ahmed M, Taha, Sheena, Marks, Elisabeth, Pach, Beata, Ahamad, Keith, Grennell, Erin, Holowaty, Melissa, Manson, Heather, Straus, Sharon E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2019
Gaiak:
Addiction
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924699/
https://ncbi.nlm.nih.gov/pubmed/31843837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-032285
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak